Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
Peer Reviewed
See detailClinical cases of anemia
Amory, Hélène ULg

in In proceedings of the II Encontro de Formação da Ordem dos Médicos Veterinários (2011, October 08)

Detailed reference viewed: 10 (1 ULg)
Peer Reviewed
See detailClinical cases of icterus
Amory, Hélène ULg

in In proceedings of the II Encontro de Formação da Ordem dos Médicos Veterinários (2011, October 08)

Detailed reference viewed: 18 (0 ULg)
See detailClinical cases presentation
Van Heusden, Alain ULg

Scientific conference (2008)

Detailed reference viewed: 5 (0 ULg)
See detailClinical Cases. Workshop
Brichant, Jean-François ULg; Magnusson, L.

Conference (2007, June)

Detailed reference viewed: 2 (0 ULg)
Full Text
Peer Reviewed
See detailClinical characteristics and therapeutic responses in patients with Germ-line AIP mutations and pituitary adenomas : An international collaborative study
Daly, Adrian ULg; Tichomirowa, Maria A.; Petrossians, Patrick ULg et al

in Journal of Clinical Endocrinology and Metabolism (2010), 95(11),

Context: AIP mutations (AIPmut) give rise to a pituitary adenoma predisposition that occurs in familial isolated pituitary adenomas and less often in sporadic cases. The clinical and therapeutic features ... [more ▼]

Context: AIP mutations (AIPmut) give rise to a pituitary adenoma predisposition that occurs in familial isolated pituitary adenomas and less often in sporadic cases. The clinical and therapeutic features of AIPmut-associated pituitary adenomas have not been studied comprehensively. <br />Objective: The objective of the study was to assess clinical/therapeutic characteristics of AIPmut pituitary adenomas. <br />Design: This study was an international, multicenter, retrospective case collection/database analysis. <br />Setting: The study was conducted at 36 tertiary referral endocrine and clinical genetics departments. <br />Patients: Patients included 96 patients with germline AIPmut and pituitary adenomas and 232 matched AIPmut-negative acromegaly controls. <br />Results: The AIPmut population was predominantly young and male (63.5%); first symptoms occurred as children/adolescents in 50%. At diagnosis, most tumors were macroadenomas (93.3%); extension and invasion was common. Somatotropinomas comprised 78.1% of the cohort; there were also prolactinomas (n = 13), nonsecreting adenomas (n = 7), and a TSH-secreting adenoma. AIPmut somatotropinomas were larger (P = 0.00026), with higher GH levels (P = 0.00068), more frequent extension (P = 0.018) and prolactin cosecretion (P = 0.00023), and occurred 2 decades before controls (P < 0.000001). Gigantism was more common in the AIPmut group (P < 0.000001). AIPmut somatotropinoma patients underwent more surgical interventions (P = 0.00069) and had lower decreases in GH (P = 0.00037) and IGF-I (P = 0.028) and less tumor shrinkage with somatostatin analogs (P < 0.00001) vs. controls. AIPmut prolactinomas occurred generally in young males and frequently required surgery or radiotherapy. <br />Conclusions: AIPmut pituitary adenomas have clinical features that may negatively impact treatment efficacy. Predisposition for aggressive disease in young patients, often in a familial setting, suggests that earlier diagnosis of AIPmut pituitary adenomas may have clinical utility. [less ▲]

Detailed reference viewed: 111 (48 ULg)
Full Text
Peer Reviewed
See detailClinical characteristics of patients responsive to whole body vibration
Beaudart, Charlotte ULg; Buckinx, Fanny ULg; Maquet, Didier ULg et al

in Osteoporosis International (2013, April), 24(Suppl.1), 243

Detailed reference viewed: 44 (14 ULg)
Full Text
See detailClinical characteristics of patients with AIP mutation-related prolactinomas
Camby, S; Daly, Adrian ULg; VROONEN, Laurent ULg et al

in Abstract book - Symposium "Perspectives in Endocrinology" Congresses Highlights 2013:ECE Copenhagen, ENDO SF, SFE Paris (2014, February)

Detailed reference viewed: 14 (2 ULg)
Full Text
See detailThe clinical characteristics of pituitary adenomas (PA) in patients with primary hyperparathyroidism (PHPT) with and without MEN1 mutation
Filipponi, S; Rostomyan, Liliya ULg; VALDES SOCIN, Hernan Gonzalo ULg et al

in Symposium "Perspectives in Endocrinology" - Congresses Highlights 2012: ECE Firenze, ENDO Houston, ESPE Leipzig, SFE Toulouse, IWMEN Liège (2013)

Detailed reference viewed: 9 (4 ULg)
Full Text
See detailThe Clinical characteristics of pituitary adenomas in patients with primary hyperparathyroidism (PHPT) with and without MEN1 mutation
Rostomyan, Liliya ULg; Tichomirowa, M.; Kirdyankina, N. et al

in ENEA Munich - abstract book (2011, December)

Detailed reference viewed: 10 (0 ULg)
Full Text
Peer Reviewed
See detailClinical characteristics, prognosis and treatment for pelvic cryptorchid seminoma
Li; COUCKE, Philippe ULg; Qian et al

in International Journal of Radiation, Oncology, Biology, Physics (1997), 38(2), 351-357

Purpose: To analyze the clinical characteristics, prognosis, and treatment outcome of pelvic cryptorchid seminoma (PCS), and to determine whether whole abdominal-pelvic irradiation for Stage I disease is ... [more ▼]

Purpose: To analyze the clinical characteristics, prognosis, and treatment outcome of pelvic cryptorchid seminoma (PCS), and to determine whether whole abdominal-pelvic irradiation for Stage I disease is necessary. Methods and Materials: From 1958 to 1991,60 patients with PCS were treated at the Cancer Hospital of Chinese Academy of Medical Sciences, Beijing. They presented with a lower abdominal mass and showed a predominance for the right side. A high proportion of patients with PCS [ 26 of 60 (43% )] had metastatic disease, compared to 20% of those with scrotal seminoma, and there was a tendency toward a higher frequency of pelvic nodal metastases. There were 34 Stage I, 6 Stage IIA, 11 Stage IIB, 5 Stage III, and 4 Stage IV patients. Of these 60 patients, 56 underwent laparotomy with or without cryptorchiectomy (37 radical orchiectomy, 7 partial orchiectomy, and 12 biopsy of the primary or cervical node), and 4 cervical node biopsy only. All patients were further treated with radiotherapy, chemotherapy, or a combination of both. Patients with Stage I and II disease received radiotherapy, whereas patients with Stage III and IV were treated with chemotherapy. Results: The overall and disease-free survivals at 5 and 10 years were 92% and 87%, and 88% and 84%, respectively. The 5- and lo-year survivals were 100% for Stage I, 94% and 87% for Stage II, and 56% and 42% for Stage III/IV, respectively @ < 0.05). Volume of irradiation, i.e., whole abdominal-pelvic radiotherapy ( 10 patients), versus hockey-stick encompassing paraaortic, ipsilateral iliac nodes and the primary tumor or tumor bed (17) did not influence outcome in Stage I patients. Five patients relapsed within 2-12 years after treatment, and four of these patients were successfully salvaged. Four patients developed a second malignant tumor and died. Conclusion: Stage I and II PCS can he adequately controlled by radiotherapy regardless of the surgical procedure. Whole abdominal-pelvic irradiation for Stage I and IIA disease is not required, and fields can be limited to the paraaortic, ipsilateral iliac nodes and primary tumor or tumor bed. We recommend platinum-based chemotherapy for Stage IIB-IV PCS. 0 1997 Elsevier Science Inc. [less ▲]

Detailed reference viewed: 23 (2 ULg)
Full Text
Peer Reviewed
See detailClinical characterization of cabergoline resistant prolactinomas : a multicenter experience on 92 patients
VROONEN, Laurent ULg; Jaffrain Rea, ML; PETROSSIANS, Patrick ULg et al

in Annales d'Endocrinologie (2012, April), 73(2), 153

Detailed reference viewed: 29 (5 ULg)
Full Text
See detailClinical characterization of cabergoline resistant prolactinomas : a multicenter experience on 92 patients
VROONEN, Laurent ULg; Jaffrain-Rea, M. L.; PETROSSIANS, Patrick ULg et al

in ENEA Munich - abstract book (2011, December)

Detailed reference viewed: 22 (4 ULg)
Full Text
Peer Reviewed
See detailClinical characterization of familial isolated pituitary adenomas.
Daly, Adrian ULg; Jaffrain-Rea, M.-L.; Ciccarelli, A. et al

in Journal of Clinical Endocrinology and Metabolism (2006), 91(9), 3316-23

CONTEXT: Familial pituitary adenomas occur rarely in the absence of multiple endocrine neoplasia type 1 (MEN1) and Carney complex (CNC). OBJECTIVE: Our objective was to characterize the clinical and ... [more ▼]

CONTEXT: Familial pituitary adenomas occur rarely in the absence of multiple endocrine neoplasia type 1 (MEN1) and Carney complex (CNC). OBJECTIVE: Our objective was to characterize the clinical and genealogical features of non-MEN1/CNC familial isolated pituitary adenomas (FIPA). DESIGN AND SETTING: We conducted a retrospective study of clinical and genealogical characteristics of FIPA cases and performed a comparison with a sporadic population at 22 university hospitals in Belgium, Italy, France, and The Netherlands. RESULTS: Sixty-four FIPA families including 138 affected individuals were identified [55 prolactinomas, 47 somatotropinomas, 28 nonsecreting adenomas (NS), and eight ACTH-secreting tumors]. Cases were MEN1/PRKAR1A-mutation negative. First-degree relationships predominated (75.6%) among affected individuals. A single tumor phenotype occurred in 30 families (homogeneous), and heterogeneous phenotypes occurred in 34 families. FIPA cases were younger at diagnosis than sporadic cases (P = 0.015); tumors were diagnosed earlier in the first vs. the second generation of multigenerational families. Macroadenomas were more frequent in heterogeneous vs. homogeneous FIPA families (P = 0.036). Prolactinomas from heterogeneous families were larger and had more frequent suprasellar extension (P = 0.004) than sporadic cases. Somatotropinomas occurred as isolated familial somatotropinoma cases and within heterogeneous FIPA families; isolated familial somatotropinoma cases represented 18% of FIPA cases and were younger at diagnosis than patients with sporadic somatotropinomas. Familial NS cases were younger at diagnosis (P = 0.03) and had more frequently invasive tumors (P = 0.024) than sporadic cases. CONCLUSIONS: Homogeneous and heterogeneous expression of prolactinomas, somatotropinomas, NS, and Cushing's disease can occur within families in the absence of MEN1/CNC. FIPA and sporadic cases have differing clinical characteristics. FIPA may represent a novel endocrine neoplasia classification that requires further genetic characterization. [less ▲]

Detailed reference viewed: 28 (6 ULg)
Full Text
Peer Reviewed
See detailClinical comparison between nasopharyngeal, oropharyngeal and laryngopharyngeal disorders in dogs and cats: a review of 80 cases.
Billen, Frédéric ULg; Peeters, Dominique ULg; Day, Michael et al

in Proceedings of the 13th ECVIM-CA Congress (4-6/09/2003), Uppsala, Sweden (2003, September)

Detailed reference viewed: 10 (3 ULg)
Full Text
Peer Reviewed
See detailClinical comparison in BMD gains with monthly oral ibandronate (150 mg) and weekly oral alendronate (70 mg) : results from the MOTION study
Miller, P. D.; Zerbini, C. A. F.; Recker, R. R. et al

in Journal of Bone and Mineral Research (2007), 22(S1), 451

Detailed reference viewed: 8 (1 ULg)
Peer Reviewed
See detailA clinical comparison of sumatriptan nasal spray and dihydroergotamine nasal spray in the acute treatment of migraine.
Boureau, F.; Kappos, L.; Schoenen, Jean ULg et al

in International Journal of Clinical Practice (2000), 54(5), 281-6

A multinational, multicentre, randomised, double-blind, double-dummy, crossover study (368 patients treating two attacks) was conducted to compare the efficacy and tolerability of sumatriptan nasal spray ... [more ▼]

A multinational, multicentre, randomised, double-blind, double-dummy, crossover study (368 patients treating two attacks) was conducted to compare the efficacy and tolerability of sumatriptan nasal spray (20 mg) with dihydroergotamine (DHE) nasal spray (1 mg plus optional 1 mg). At the primary efficacy time point of 60 minutes after dosing, significantly more patients obtained headache relief (change from moderate or severe to none or mild) after treatment with sumatriptan than with DHE (53% sumatriptan, 41% DHE, p < 0.001). Significantly more patients reported relief of nausea after sumatriptan than after DHE at 60 minutes (64% sumatriptan, 49% DHE, p = 0.006). A significant difference between the two treatments was first observed at 45 minutes with respect to both headache relief (38% sumatriptan, 31% DHE, p = 0.037) and relief of nausea (55% sumatriptan, 40% DHE, p = 0.014). There were no significant differences between the two treatments for other measures of efficacy. Both treatments were well tolerated, with only 10% of patients in each group reporting one or more adverse events. The most frequently reported adverse event after sumatriptan was a bad or bitter taste, which was reported by 5% of patients. After DHE, 4% of patients reported symptoms of the nasal cavity/sinuses and 3% reported nausea and/or vomiting as adverse events. It is concluded that sumatriptan nasal spray is superior to DHE nasal spray in the relief of pain and nausea associated with acute migraine headache. [less ▲]

Detailed reference viewed: 45 (0 ULg)
Full Text
Peer Reviewed
See detailClinical contribution of PET neurotransmission imaging in neurological disorders
Garraux, Gaëtan ULg; Salmon, Eric ULg

in Acta Neurologica Belgica (2005), 105(3), 119-136

Imaging neurotransmission in vivo using positron emission tomography (PET) is a rapidly expanding clinical science. The present review summarizes the actual contribution of PET imaging to clinical ... [more ▼]

Imaging neurotransmission in vivo using positron emission tomography (PET) is a rapidly expanding clinical science. The present review summarizes the actual contribution of PET imaging to clinical problems in movement and seizure disorders and dementia. [less ▲]

Detailed reference viewed: 25 (6 ULg)
Full Text
Peer Reviewed
See detailClinical course and predictive factors for cyclosporin-induced autologous graft-versus-host disease after autologous haematopoietic stem cell transplantation.
Baron, Frédéric ULg; Gothot, André ULg; Salmon, Jean ULg et al

in British Journal of Haematology (2000), 111(3), 745-53

The administration of cyclosporin A (CyA) after autologous haematopoietic stem cell transplantation (HSCT) induces a systemic autoimmune syndrome mimicking graft-vs.-host disease (GVHD). This syndrome ... [more ▼]

The administration of cyclosporin A (CyA) after autologous haematopoietic stem cell transplantation (HSCT) induces a systemic autoimmune syndrome mimicking graft-vs.-host disease (GVHD). This syndrome, termed autologous GVHD has notable anti-tumour activity in animal studies. We intended to induce autologous GVHD with CyA in patients undergoing an autologous HSCT. We prospectively studied 118 patients with miscellaneous malignancies undergoing an autologous HSCT with low-dose CyA to characterize the clinical syndrome, its frequency and clinical course, and to determine the factors affecting its incidence. Patients received CyA from d -1 through to d 28, first starting at 2 mg/kg intravenously and then orally as soon as feasible. The dose was adjusted to achieve pre-dose blood levels around 100 ng/ml. A skin biopsy was performed when a skin rash was observed. Thirty-three percent of the patients developed clinical GVHD: clinical stage 1 in 21 patients, stage 2 in seven patients, and stage 3 in three patients. Although total body irradiation (TBI) or high-dose cyclophosphamide were previously thought to be needed, autologous GVHD occurred in five out of 12 patients (42%) after a preparative regimen with high-dose melphalan alone. Autologous GVHD was significantly more frequent in patients older than 33 years, in patients who had received high doses of granulocyte-macrophage colony forming units (CFU-GM) and in those with a diagnosis of myeloid malignancy, compared with those with lymphoid malignancies or solid tumours. A significant negative association was also found with HLA-DR6. In lymphoma patients, GVHD occurred more frequently in advanced disease than in first or second complete remission (CR1-2) patients. All other factors studied were not predictive for GVHD. In conclusion, CyA-induced GVHD is reproducibly and safely induced with doses of CyA adapted to achieve blood levels around 100 ng/ml. In retrospective analysis, there was no survival advantage for patients with GVHD. Phase III trials with this approach are needed to evaluate its anti-tumoral effect. [less ▲]

Detailed reference viewed: 23 (0 ULg)
Full Text
Peer Reviewed
See detailClinical data based optimal STI strategies for HIV: a reinforcement learning approach
Ernst, Damien ULg; Stan, Guy-Bart; Gonçalves, Jorge et al

in Proceedings of the 45th IEEE Conference on Decision and Control (CDC 2006) (2006)

This paper addresses the problem of computing optimal structured treatment interruption strategies for HIV infected patients. We show that reinforcement learning may be useful to extract such strategies ... [more ▼]

This paper addresses the problem of computing optimal structured treatment interruption strategies for HIV infected patients. We show that reinforcement learning may be useful to extract such strategies directly from clinical data, without the need of an accurate mathematical model of HIV infection dynamics. To support our claims, we report simulation results obtained by running a recently proposed batch-mode reinforcement learning algorithm, known as fitted Q iteration, on numerically generated data. [less ▲]

Detailed reference viewed: 22 (8 ULg)